Indeed, galcanezumab has a peripheral site of action, and the peripheral CGRP pathway has a marginal importance in the pathogenesis of the psychiatric comorbidities of CM and MOH (Goadsby et al., 2019; Hashikawa‐Hobara et al., 2021). Here, CALCA is linked to cutaneous mastocytosis.